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Summary
Background Insulin-like growth factor 1 (IGF1) stimulates mitosis and inhibits apoptosis. Some published results 
have shown an association between circulating IGF1 and breast-cancer risk, but it has been unclear whether this 
relationship is consistent or whether it is modiﬁ ed by IGF binding protein 3 (IGFBP3), menopausal status, oestrogen 
receptor status or other factors. The relationship of IGF1 (and IGFBP3) with breast-cancer risk factors is also unclear. 
The Endogenous Hormones and Breast Cancer Collaborative Group was established to analyse pooled individual data 
from prospective studies to increase the precision of the estimated associations of endogenous hormones with breast-
cancer risk.
Methods Individual data on prediagnostic IGF1 and IGFBP3 concentrations were obtained from 17 prospective 
studies in 12 countries. The associations of IGF1 with risk factors for breast cancer in controls were examined by 
calculating geometric mean concentrations in categories of these factors. The odds ratios (ORs) with 95% CIs of 
breast cancer associated with increasing IGF1 concentrations were estimated by conditional logistic regression in 
4790 cases and 9428 matched controls, with stratiﬁ cation by study, age at baseline, and date of baseline. All statistical 
tests were two-sided, and a p value of less than 0·05 was considered signiﬁ cant.
Findings IGF1 concentrations, adjusted for age, were positively associated with height and age at ﬁ rst pregnancy, 
inversely associated with age at menarche and years since menopause, and were higher in moderately overweight 
women and moderate alcohol consumers than in other women. The OR for breast cancer for women in the highest 
versus the lowest ﬁ fth of IGF1 concentration was 1·28 (95% CI 1·14–1·44; p<0·0001). This association was not 
altered by adjusting for IGFBP3, and did not vary signiﬁ cantly by menopausal status at blood collection. The ORs 
for a diﬀ erence in IGF1 concentration between the highest and lowest ﬁ fth were 1·38 (95% CI 1·14–1·68) for 
oestrogen-receptor-positive tumours and 0·80 (0·57–1·13) for oestrogen-receptor-negative tumours (p for 
heterogeneity=0·007).
Interpretation Circulating IGF1 is positively associated with breast-cancer risk. The association is not substantially 
modiﬁ ed by IGFBP3, and does not diﬀ er markedly by menopausal status, but seems to be conﬁ ned to oestrogen-
receptor-positive tumours.
Funding Cancer Research UK.
Introduction
Insulin-like growth factor 1 (IGF1) is a peptide which 
stimulates mitosis and inhibits apoptosis.1,2 Interest in 
the role of IGF1 in the development of breast cancer 
began in the 1980s.3,4 An early case-control study reported 
higher plasma concentrations of IGF1 in women with 
breast cancer than in controls,5 and in the ﬁ rst prospective 
study plasma concentrations of IGF1 were positively 
associated with breast-cancer risk for premenopausal 
women, but not for postmenopausal women.6 Some, but 
not all, subsequent prospective studies have supported a 
positive association between IGF1 and breast-cancer risk, 
but have been inconsistent as to whether the association 
diﬀ ers according to menopausal status.7–22
Around 99% of IGF1 circulates bound to IGF binding 
proteins, with most bound to IGF binding protein 3 
(IGFBP3) in a ternary complex with an acid labile 
subunit. Less than 1% of IGF1 circulates unbound.1 Most 
prospective studies of IGF1 and breast-cancer risk have 
also reported on IGFBP3, to explore the hypothesis that 
women with a high concentration of IGF1 relative to 
IGFBP3 are at an increased risk of breast cancer.23 
However, the results of these analyses have been 
inconsistent. Fewer studies have measured free IGF1, 
IGF2 or other IGFBPs, such as IGFBP1 and IGFBP2.  
Oestrogens are important in the aetiology of breast 
cancer, and there is laboratory evidence for crosstalk in 
cells between the signalling pathways for oestrogens and 
IGF1.24 It is therefore important to examine whether the 
association of IGF1 with breast-cancer risk varies 
according to the oestrogen-receptor status of the tumour 
or circulating concentrations of oestradiol. 
The Endogenous Hormones and Breast Cancer 
Collaborative Group was established to do pooled analyses 
of individual data from prospective studies to increase 
the precision of the estimated associations of endogenous 
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hormones with breast-cancer risk.25 In this study we 
undertook a collaborative analysis of data from 17 studies 
to investigate the associations of IGF1 and IGFBP3 with 
breast-cancer risk. We also examined consistency 
between studies, associations in subgroups including 
menopausal status at blood collection and oestrogen 
receptor status, the eﬀ ects of adjustment of IGF1 and 
IGFBP3 for each other and for other risk factors, and the 
joint associations of IGF1, oestradiol, and testosterone 
with breast cancer risk in postmenopausal women.
Methods
Data collection
Studies were eligible for the collaborative analysis if they 
had prospectively collected blood samples and data on 
circulating IGF1, IGFBP3, and breast-cancer risk. 
Potentially eligible studies were identiﬁ ed through 
PubMed using the terms “IGF1”, “IGFBP3”, and “breast 
cancer”, by searching the reference lists of identiﬁ ed 
studies, and by correspondence with study investigators. 
17 eligible studies were identiﬁ ed: CLUE I and CLUE II 
from the USA;17 European Prospective Investigation into 
Cancer and Nutrition (EPIC), from Europe;16 Guernsey 
study, from the UK;13 Janus biobank study, from Norway;20 
Danish Diet, Cancer, and Health study (KKH), from 
Denmark;12 Kaiser Permanente-Orentreich Foundation 
Study (KP-OFAS) study, from the USA;9 Malmö and 
Northern Sweden studies, from Sweden;8 Melbourne 
Collaborative Cohort Study (MCCS), from Australia;19 
Nurses’ Health Study, from the USA;6,15 Nurses’ Health 
Study II, from the USA;18 New York University Women’s 
Health Study (NYU WHS), from the USA;7 Study of 
Hormones and Diet in the Etiology of Breast Tumours 
(ORDET), from Italy;10 Prostate, Lung, Colorectal, and 
Ovarian Cancer Screening Trial (PLCO), from the USA;22 
Monitoring Project on Cardiovascular Disease Risk Factors 
Recruitment 
period
Fasting status Storage 
temperature
Matching criteria
Age at blood 
collection
Date of blood sample Other matching criteria and comments
CLUE I and CLUE II, USA17 1974 and 1989 Non-fasting –70°C ±1 year ±14 days Participation in one or both cohorts, menopausal status, 
ethnic group, freeze and thaw history of serum sample
EPIC, Europe16 1992–98 Matched Mostly –196°C* ±6 months No (incidence density 
sampling) 
Time of day at blood collection, menopausal status, phase of 
cycle in premenopausal, subcohort
Guernsey, UK13 1977–91 Non-fasting –20°C ±2 years ±1 year Menopausal status, phase of cycle in premenopausal
Janus Biobank, Norway20 1986–97 Non-fasting –25°C All 40–42 years ±6 months Originally unmatched; matched sets created for this analysis
KKH, Denmark12 1993–97 Non-fasting –150°C Same half-year No Known or probable postmenopausal
KP-OFAS, USA9 1964–71 Non-fasting –23°C until 
1980 then –40°C
Age ±1 year Menopausal status
Malmö/Umeå, Sweden8 1985–98 Some matched, 
some non-fasting
–80 C ±1 year ±1 year Menopausal status
MCCS, Australia19 1990–94 Non-fasting <–120°C ±24 months ±24 months Originally a case-cohort study; matched sets created for this 
analysis
Nurses’ Health Study, 
USA6,15
1989–90 Matched, mostly 
fasting
–130°C Same year of 
birth
Same month and year Time of day, menopausal status at blood collection and 
diagnosis, fasting status
Nurses’ Health Study II, 
USA18
1996–99 Matched, mostly 
fasting
–130°C Same year of 
birth
Same month and year Time of day, menopausal status at diagnosis, fasting status, 
luteal day of sample
NYU WHS, USA7 1985–91 Non-fasting –80°C ±3 months ±3 months Menopausal status, phase of cycle in premenopausal
ORDET, Italy10 1987–92 12 hour fast prior to 
collection. Samples 
taken 07:30–09:00
–80°C ± 5 years ±89 days Menopausal status, daylight saving period, recruitment 
centre
PLCO, USA22 1993–2001 Non-fasting –80°C ±24 months ±24 months Originally a case-cohort study; matched sets created for this 
analysis
PPHV, Netherlands11 1987–91 Non-fasting –20°C ±1 year Same month and year Place of residence
Prospect-EPIC, 
Netherlands11
1993–97 Non-fasting –80°C initially 
then -196°C
±1 year Same month and year None
SOF, USA26 1986–88 Fat-free overnight 
and morning diet
–120°C ±24 months ±24 months Originally a case-cohort study; matched sets created for this 
analysis
WHI-OS, USA21 1993–98 Fasting –70°C ±24 months ±24 months Originally a case-cohort study; matched sets created for this 
analysis
*Stored in liquid nitrogen at –196°C, except in Denmark in nitrogen vapour at –150°C, and in Sweden in electric freezers at –80 °C. EPIC=European Prospective Investigation into Cancer and Nutrition. 
KKH=Danish Diet, Cancer, and Health study. KP-OFAS=Kaiser Permanente-Orentreich Foundation Study. MCCS=Melbourne Collaborative Cohort Study. NYU WHS=New York University Women’s Health Study. 
ORDET=Study of Hormones and Diet in the Etiology of Breast Tumours. PLCO=Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. PPHV=Monitoring Project on Cardiovascular Disease Risk Factors. 
SOF=Study of Osteoporotic Fractures. WHI-OS=Women’s Health Initiative, Observational Study.  
Table 1: Description of studies
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(PPHV) and Prospect-EPIC, from the Netherlands;11 Study 
of Osteoporotic Fractures (SOF), from the USA;26 and the 
Women’s Health Initiative, Observational Study (WHI-
OS), from the USA.21
Table 1 summarises the study designs. Details of the 
recruitment of participants, informed consent, ethics 
approvals, and deﬁ nitions of reproductive variables are in 
the original publications. Collaborators were asked to 
provide data on concentrations of IGF1 and IGFBP3, and 
also on the sex hormones oestradiol and testosterone. 
Details of the assay methods for IGF1 and IGFBP3 are 
shown in table 2; 10 studies used serum, six used plasma, 
and one used both, but for convenience we refer to plasma 
concentrations throughout this paper. Details of the assay 
methods for the sex hormones are in the original 
publications. Collaborators also provided data on 
reproductive, anthropometric, and other characteristics 
for each woman in their study. Menopausal status at the 
time of blood collection was deﬁ ned on the basis of 
questions about the number of menstrual periods in the 
previous year and details of any hysterectomy and 
ovariectomy; the details varied slightly between studies 
and are in the original publications. Women were excluded 
from the analyses if they were perimenopausal or of 
unknown menopausal status, if they were using hormone-
replacement therapy or other exogenous sex hormones at 
the time of blood collection, or if data were missing for 
dates of birth, blood collection, or diagnosis (for cases). 
Statistical analysis
Of the 17 studies that contributed data, 11 provided data for 
women who were premenopausal at blood collection, and 
15 provided data for women who were postmenopausal at 
blood collection. Data from premenopausal women and 
postmenopausal women in the same cohort were treated 
as separate sub-cohorts. For the cross-sectional analyses, 
data were included from all women in the original studies 
who had not been diagnosed with breast cancer (n=10 022); 
in the analyses of breast-cancer risk the data were arranged 
in matched sets, and some potential controls were not 
matched; therefore, the number of controls with data on 
IGF1 is less in the risk analyses (n=9428).
Concentrations of IGF1 and IGFBP3 were positively 
skewed; therefore, log-transformed concentrations were 
used for all parametric analyses. Correlations between 
IGF1 and IGFBP3 among premenopausal and post-
menopausal controls were calculated using standardised 
log-transformed concentrations within each study, the 
standardised values being calculated by subtracting the 
mean log concentration and dividing by the standard 
deviation of the log concentration. The associations of 
IGF1 with risk factors for breast cancer were examined 
in the controls using linear regression, calculating 
geometric mean concentrations and 95% CIs according 
to categories of these factors. Geometric means were 
adjusted for study and age (age categories as in ﬁ gure 1), 
as appropriate. F tests were used to test for heterogeneity 
Sample IGF1 assay Intra-assay CV Inter-assay CV IGFBP3 assay Intra-assay CV Inter-assay CV
CLUE I and CLUE II, USA17 Phase 1 serum;
phase 2 plasma
ELISA (DSL) Serum 4·0%;
plasma 3·2%
Serum 5·9%;
plasma 5·9%
ELISA (DSL) Serum 5·9%
Plasma 3·7%
Serum 6·0%
Plasma 6·5%
EPIC, Europe16 Serum ELISA (DSL) 6·2% 16·2% ELISA (DSL) 7·2% 9·7%
Guernsey, UK13 Serum ELISA (DSL) Overall CV 6·6% ·· RIA (in-house) Overall CV 3·9% ··
Janus Biobank, Norway20 Serum RIA (in-house) 8% 10% RIA (in-house) 5% 8%
KKH, Denmark12 Serum TRIFMA (DELFIA) <5% <10% IRMA (DSL) <5% <10%
KP-OFAS, USA9 Serum RIA (NID) 6·3% 7·0% IRMA (DSL) 2·1% 5·3%
Malmö/Umeå, Sweden8 Heparin plasma IRMA (DSL) 13·6% 5·3% IRMA (DSL) 7·1% 3·1%
MCCS, Australia19 Heparin plasma ELISA (DSL) 9% 7% ELISA (DSL) 8% 3%
Nurses’ Health Study, USA6,15 Heparin plasma ELISA (DSL) 8·7% 15·6% ELISA (DSL) 9·3% 19·4%
Nurses’ Health Study II, USA18 Heparin plasma ELISA (DSL) 6·8% ·· ELISA (DSL) 4·2% ··
NYU WHS, USA7 Serum RIA (in-house) 5·9% 7·9% RIA (in-house) 6·9% 10·8%
ORDET, Italy10 Serum IRMA (DSL) 4·5% ·· IRMA (DSL) 4·3% ··
PLCO, USA22 Serum ELISA (DSL) 4·4%
Overall CV 5·1% ··
ELISA (DSL) 2·8% 
Overall CV 4·8% ··
PPHV, Netherlands11 EDTA plasma IRMA (DSL) 2·6% 6·4% IRMA (DSL) 1·1% 4·7%
Prospect-EPIC, Netherlands11 Citrate plasma IRMA (DSL) 2·6% 6·4% IRMA (DSL) 1·1% 4·7%
SOF, USA26 Serum RIA 2·2% 6·4% IRMA (DSL) 2·2% 8·0%
WHI-OS, USA21 Serum ELISA (DSL) <10% 8·2% ELISA (DSL) <10% 3·6%
IGF1=insulin-like growth factor 1. IGFBP3=IGF-binding protein 3. EPIC=European Prospective Investigation into Cancer and Nutrition. KKH=Danish Diet, Cancer, and Health 
study. KP-OFAS=Kaiser Permanente-Orentreich Foundation Study. MCCS=Melbourne Collaborative Cohort Study. NYU WHS=New York University Women’s Health Study. 
ORDET=Study of Hormones and Diet in the Etiology of Breast Tumours. PLCO=Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. PPHV=Monitoring Project on 
Cardiovascular Disease Risk Factors. SOF=Study of Osteoporotic Fractures. WHI-OS=Women’s Health Initiative, Observational Study. DELFIA=Immunoﬂ uorometric assay. 
EDTA=ethylene diamine tetraacetic acid. ELISA=Enzyme-Linked Immunosorbant Assay. IRMA=Immunoradiometric assay. RIA=Radioimmunoassay. DSL=Diagnostic Systems 
Laboratories Inc. NID=Nichols Institute Diagnostics. CV=Coeﬃ  cient of variation. TRIFMA=Time-resolved immunoﬂ uorometric assay. IRMA=Immunoradiometric assay.
Table 2:  Assay methods
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in the geometric mean hormone concentrations 
between the categories of risk factors, and where 
appropriate to test for trends across the categories, with 
the ordered categories scored from 1 to the maximum 
number of categories. The heterogeneity between 
studies in the associations of IGF1 with risk factors was 
assessed by adding a study factor interaction term to 
the model and using the F test to calculate its 
signiﬁ cance. A similar approach was used to assess 
heterogeneity according to menopausal status.
11 of the original studies contributing to the collaborative 
analysis had used matched nested case-control designs, 
and the remaining six had used unmatched controls or a 
case-cohort design (Janus,20 KKH Denmark,12 MCCS,19 
PLCO,22 SOF,26 and WHI-OS21). Some used density 
sampling, meaning that an individual participant could 
appear more than once in a data ﬁ le; in order to avoid 
double-counting women in the cross-sectional analyses, 
we created a pooled dataset in which duplicate 
observations were deleted, with the case observation 
retained where a participant appeared as both a case 
patient and a control. We retained the original matched 
sets where available, otherwise for the case-cohort studies 
we created new matched sets in which each case was 
matched with up to four controls, matching by study, 
date of blood collection (plus or minus 24 months), age at 
blood collection (plus or minus 24 months) and, for Janus 
only,20 county of residence. 
Conditional logistic regression was used to calculate the 
odds ratio (OR) for breast cancer in relation to the plasma 
concentrations of IGF1 and IGFBP3, categorising women 
in each study according to the quintiles of hormone 
concentration for the controls in that study. Study-speciﬁ c 
cut-points were used because the absolute concentrations 
of IGF1 and IGFBP3 vary between studies because of 
laboratory variation; further explanation of this approach 
is provided in previous publications.25,27 To provide a 
summary measure of risk, we calculated a linear trend by 
scoring the ﬁ fths of the plasma IGF1 or IGFBP3 
concentrations as 0, 0·25, 0·5, 0·75, and 1; under the 
assumption of linearity, a unit change in this trend 
variable is equivalent to the OR comparing the highest 
with the lowest ﬁ fth of hormone concentration.27 
Heterogeneity in linear trends among studies was 
assessed using a χ² test, calculating the χ² statistic as the 
diﬀ erence between the sum of the model χ² values for 
each study and the model χ² value from the all-studies 
analysis. We also used χ² tests to examine whether there 
was evidence of heterogeneity in the associations of IGF1 
with breast-cancer risk according to subgroups deﬁ ned by 
menopausal status at blood collection and other factors.
We examined the eﬀ ect on the association with breast-
cancer risk of adjusting IGF1 and IGFBP3 for each other. 
We also investigated the associations of IGF1 with breast-
cancer risk after adjusting, one factor at a time, for various 
established reproductive and hormonal risk factors for 
breast cancer: age at menarche (<12, 12–13, ≥14 years); 
parity (0, 1, 2, 3, ≥4 full-term pregnancies); age at ﬁ rst full-
term pregnancy (<20, 20–24, 25–29, ≥30 years); body mass 
index (BMI; <22·5, 22·5–24·9, 25·0–27·4, 27·5–29·9, 
≥30·0 kg/m²); previous use of oral contraceptives (never 
or ever); and, for postmenopausal women only, type of 
Figure 1: Geometric mean IGF1 concentrations (nmol/L with 95% CI) among controls by selected factors
Adjusted for study and age at blood collection, as appropriate. *Means are scaled to the overall geometric mean 
concentration. †p values for tests of heterogeneity and, where applicable and in parenthesis, linear trend. ‡Values 
are depicted as a proportion of the overall geometric mean concentration (dotted line). §p<0·05 for test of 
interaction with study.
Factor and subset p values†n Mean* (95% CI) Relative mean‡ and 95% CI
Age at blood collection (years)§
<45 2350 26·9 (26·3–27·6) <0·0001
45–49 1495 24·6 (24·1–25·2) (<0·0001)
50–54 1315 23·8 (23·3–24·2) 
55–59 1652 22·3 (21·8–22·8) 
60–64 1570 20·8 (20·4–21·3) 
≥65 1640 19·9 (19·4–20·3) 
Height (cm)
<155 1329 22·3 (21·9–22·7) 0·0001
155–159 2101 23·1 (22·7–23·4) (<0·0001)
160–164 2663 23·2 (22·8–23·5)
165–169 1921 23·5 (23·1–23·9)
≥170 1128 23·9 (23·4–24·4)
Body-mass index (kg/m2)§
<22·5 2094 23·0 (22·7–23·4) <0·0001
22·5–24·9 2349 23·8 (23·5–24·2) (<0·0001)
25·0–27·4 1834 24·1 (23·7–24·5)
27·5–29·9 1276 23·0 (22·5–23·4)
≥30·0 1669 21·6 (21·3–22·0)
Smoking status
Never 5283 23·2 (23·0–23·4) 0·962
Previous 2295 23·1 (22·8–23·5)
Current 1341 23·1 (22·7–23·6)
Usual alcohol consumption (g/d)§
None 3147 22·8 (22·5–23·1) 0·0004
<10 2730 23·6 (23·2–23·9) (0·433)
10–19 1123 23·6 (23·1–24·1)
≥20 832 22·6 (22·1–23·1)
Mother or sister with breast cancer
No 3720 23·2 (23·0–23·5) 0·226 
Yes 583 22·8 (22·1–23·5) 
Age at menarche (years)
<12 1487 23·7 (23·2–24·1) 0·001
12–13 4390  23·3 (23·1–23·5) (0·0002)
≥14 3158 22·8 (22·5–23·0)
Number of full–term pregnancies
None 1261 23·2 (22·7–23·6) 0·001
One 1099 23·1 (22·6–23·6) (0·060)
Two 2952  23·7 (23·4–24·0) 
Three 2003 22·8 (22·4–23·1) 
Four or more 1548 22·7 (22·3–23·2) 
Age at ﬁrst full–term pregnancy (years)
<20 615  22·2 (21·6–22·9) 0·016
20–24 3210  23·1 (22·9–23·4) (0·008)
25–29  2734  23·3 (23·0–23·6) 
≥30   1103  23·5 (23·0–24·0) 
Type of menopause (postmenopausal women only)
Natural 4125  23·3 (23·0–23·5) 0·245
Hysterectomy   716  22·7 (22·1–23·3) 
Bilateral ovariectomy 274  22·9 (21·9–23·9) 
Years since menopause (natural postmenopausal women only)§
0–4  747 24·3 (23·5–25·1) 0·004
5–14  2196  23·2 (22·8–23·6) (0·0008)
≥15  1237  22·4 (21·8–23·0) 
Use of hormonal contraceptives
Never   3928  22·9 (22·6–23·2) 0·009
Past  3962  23·4 (23·2–23·7) 
Use of hormone therapy (natural postmenopausal women only)
Never  3024 23·1 (22·8–23·4) 0·524
Past   755 23·3 (22·7–24·0) 
0·7 0·8 1·0 1·2 1·50·9
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menopause (natural or surgical); time since menopause 
(0–4, 5–14, ≥15 years; natural postmenopausal women 
only); previous use of hormone-replacement therapy 
(never or ever). For postmenopausal women, we also 
investigated the associations of IGF1 with breast-cancer 
risk after adjustment for plasma concentrations of 
oestradiol and testosterone, and the associations of IGF1 
with breast-cancer risk with joint classiﬁ cation according 
to plasma oestradiol and testosterone concentrations.
All statistical tests were two-sided, and statistical 
signiﬁ cance was set at the 5% level. All analyses were 
done using Stata version 9.0. 
Role of the funding source
The funding source had no role in study design, data 
collection, data analysis, data interpretation, or the 
writing of the report. The members of the writing team 
had full access to all data in the study. The corresponding 
author had the ﬁ nal responsibility for the decision to 
submit for publication.
Results
Table 3 shows the characteristics of the cases and controls 
in each study. There were 4790 cases and 9428 matched 
controls. Mean age at baseline ranged from 35·5 (SD 7·8) 
to 47·7 (SD 3·1) for premenopausal women, and from 
54·3 (SD 6·1) to 71·8 (SD 4·9) for postmenopausal 
women. Most women had had a full-term pregnancy, and 
most postmenopausal women had reported a natural 
menopause. Across the studies, mean BMI ranged from 
23·1 (SD 3·5) to 28·4 (SD 6·3) kg/m², and the median 
time between blood collection and diagnosis ranged from 
1 (IQR 0–3) to 17 (IQR 8–18) years. Geometric mean 
concentrations of IGF1 ranged from 19·3 (95% CI 
Number Age (years) Nulliparous, 
n (%)
Natural menopause, 
n (%)
BMI (kg/m2) Years to 
diagnosis*
Geometric mean (95% CI) 
IGF1, nmol/L
Geometric mean (95% CI) 
IGFBP3, nmol/L
Premenopausal at blood collection
CLUE I & CLUE II, USA17
Cases 87 43·1 (6·1) 5 (19%) ·· 26·7 (5·9) 11 (8–22) 25·3 (23·3–27·5) 68·0 (65·7–70·4)
Controls 87 43·0 (6·0) 2 (8%) ·· 25·9 (4·4) ·· 24·7 (22·7–26·8) 68·7 (66·3–71·1)
EPIC, Europe16
Cases 409 45·5 (4·8) 66 (17%) ·· 24·9 (4·3) 2 (1–4) 33·9 (32·9–34·9) 119·6 (115·6–123·9)
Controls 793 45·4 (4·8) 110 (15%) ·· 25·3 (4·3) ·· 33·7 (32·9–34·4) 116·6 (113·7–119·6)
Guernsey, UK13
Cases 69 40·6 (4·8) 6 (9%) ·· 24·7 (3·7) 14 (10–16) 21·5 (19·8–23·4) 159·3 (151·1–168·0)
Controls 200 40·5 (4·4) 24 (12%) ·· 24·2 (3·9) ·· 22·1 (21·3–22·9) 168·7 (164·5–173·0)
Janus Biobank, Norway20
Cases 323 40·5 (0·5) ·· ·· ·· 4 (2–6) 27·0 (26·2–27·8) 176·8 (172·3–181·5)
Controls 639 40·6 (0·8) ·· ·· ·· ·· 26·2 (25·6–26·8) 179·4 (175·9–183·0)
KP-OFAS, USA9
Cases 89 35·7 (7·9) 18 (21%) ·· 23·9 (5·3) 13 (8–18) 31·7 (29·5–34·2) 81·3 (76·5–86·4)
Controls 89 35·5 (7·8) 19 (22%) ·· 23·6 (4·4) ·· 30·5 (28·3–32·8) 79·7 (74·9–84·8)
Malmö-Umeå, Sweden8
Cases 141 47·1 (5·0) 9 (7%) ·· 24·5 (4·0) 2 (1–4) 24·1 (22·6–25·7) 126·3 (121·8–130·9)
Controls 256 47·1 (4·9) 11 (5%) ·· 24·8 (4·1) ·· 23·6 (22·5–24·7) 124·8 (121·1–128·6)
MCCS, Australia19
Cases 160 46·8 (4·2) 38 (24%) ·· 26·0 (4·9) 4 (2–7) 23·2 (22·0–24·6) 107·6 (104·1–111·2)
Controls 594 46·1 (4·0) 94 (16%) ·· 26·2 (5·1) ·· 24·1 (23·4–24·7) 110·9 (109·1–112·7)
Nurses’ Health Study, USA6,15
Cases 194 47·7 (3·1) 13 (7%) ·· 24·5 (4·2) 7 (3–8) 27·4 (26·1–28·8) 127·6 (123·1–132·2)
Controls 262 47·6 (3·1) 13 (5%) ·· 25·4 (5·0) ·· 27·0 (25·9–28·1) 129·2 (125·4–133·1)
Nurses’ Health Study II, USA18
Cases 231 43·6 (4·0) 53 (23%) ·· 24·9 (5·1) 2 (1–4) 31·0 (29·8–32·2) 172·9 (169·7–176·3)
Controls 454 43·3 (3·8) 84 (19%) ·· 25·3 (6·1) ·· 30·8 (29·9–31·8) 172·6 (170·1–175·1)
NYU WHS, USA7
Cases 172 44·4 (4·8) 78 (51%) ·· 23·9 (4·0) 5 (3–6) 26·8 (25·5–28·1) 115·6 (111·0–120·5)
Controls 483 44·2 (4·7) 175 (41%) ·· 24·5 (4·5) ·· 26·4 (25·7–27·2) 112·7 (110·3–115·2)
ORDET, Italy10
Cases 62 44·3 (5·0) 8 (13%) ·· 24·1 (3·7) 1 (0–3) 20·9 (19·0–23·0) 127·6 (119·2–136·7)
Controls 239 43·8 (4·5) 25 (11%) ·· 24·4 (4·1) ·· 19·3 (18·4–20·3) 120·1 (115·0–125·4)
(Continues on next page)
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Number Age (years) Nulliparous, 
n (%)
Natural menopause, 
n (%)
BMI (kg/m2) Years to 
diagnosis*
Geometric mean (95% CI) 
IGF1, nmol/L
Geometric mean (95% CI) 
IGFBP3, nmol/L
(Continued from previous page)
Postmenopausal at blood collection
CLUE I & CLUE II, USA17
Cases 73 60·6 (5·2) 5 (12%) 38 (86%) 26·5 (5·5) 7 (3–10) 22·0 (19·8–24·4) 72·6 (69·8–75·4)
Controls 73 60·3 (5·2) 6 (13%) 36 (77%) 25·3 (5·5) ·· 20·3 (18·4–22·4) 69·7 (66·8–72·7)
EPIC, Europe16
Cases 677 60·1 (5·7) 84 (13%) 558 (82%) 27·2 (4·5) 2 (1–4) 28·1 (27·4–28·9) 119·9 (116·4–123·4)
Controls 1302 60·1 (5·7) 174 (14%) 1074 (82%) 26·8 (4·7) ·· 27·2 (26·7–27·7) 115·3 (112·8–117·7)
Guernsey, UK13
Cases 47 58·9 (5·8) 12 (26%) 43 (91%) 25·6 (3·5) 13 (10–15) 16·8 (15·1–18·7) 159·6 (149·0–170·9)
Controls 139 59·0 (5·8) 20 (14%) 132 (95%) 25·2 (3·5) ·· 17·0 (16·1–17·9) 159·6 (153·6–165·7)
KKH, Denmark12
Cases 195 57·5 (4·0) 30 (15%) 164 (85%) 26·3 (4·8) 2 (1–3) 17·2 (16·6–17·9) 149·6 (145·7–153·7)
Controls 195 57·5 (4·0) 29 (15%) 160 (84%) 26·3 (4·5) ·· 16·8 (16·2–17·4) 145·0 (141·4–148·7)
KP-OFAS, USA9
Cases 27 58·6 (5·9) 5 (21%) 27 (100%) 24·3 (2·2) 17 (8–18) 25·0 (22·2–28·2) 77·9 (71·8–84·6)
Controls 27 58·6 (5·9) 7 (29%) 27 (100%) 23·1 (3·5) ·· 28·2 (24·9–31·8) 77·4 (69·2–86·6)
Malmö-Umeå, Sweden8
Cases 222 60·6 (5·1) 29 (14%) 199 (90%) 26·5 (4·2) 2 (0–3) 18·1 (17·2–19·1) 122·1 (115·6–129·0)
Controls 401 60·6 (5·1) 32 (9%) 377 (94%) 25·8 (4·4) ·· 17·9 (17·0–18·8) 113·7 (107·9–119·9)
MCCS, Australia19
Cases 257 61·5 (5·2) 36 (14%) 205 (82%) 27·8 (4·7) 4 (2–6) 20·0 (19·1–20·9) 114·3 (111·1–117·5)
Controls 993 61·3 (5·1) 118 (12%) 760 (79%) 27·5 (5·0) ·· 18·6 (18·2–19·1) 109·4 (107·7–111·1)
Nurses’ Health Study, USA6,15
Cases 239 61·5 (4·7) 13 (6%) 164 (73%) 27·0 (5·4) 3 (1–4) 20·3 (19·4–21·3) 128·8 (124·1–133·7)
Controls 470 61·6 (4·7) 34 (7%) 333 (74%) 26·4 (4·7) ·· 20·1 (19·5–20·8) 130·6 (127·2–134·1)
NYU WHS, USA7
Cases 98 59·1 (3·5) 24 (30%) 78 (80%) 26·4 (4·2) 4 (3–5) 20·7 (19·4–22·2) 109·4 (103·8–115·4)
Controls 171 59·0 (3·5) 34 (23%) 138 (81%) 25·6 (4·8) ·· 20·5 (19·4–21·8) 107·3 (103·1–111·8)
ORDET, Italy10
Cases 60 58·7 (4·9) 7 (12%) 50 (83%) 26·3 (3·9) 2 (1–3) 15·2 (13·8–16·7) 128·6 (120·9–136·8)
Controls 220 58·2 (4·9) 28 (13%) 169 (77%) 26·7 (4·2) ·· 15·5 (14·7–16·5) 127·9 (123·9–132·0)
PLCO, USA22
Cases 386 63·8 (5·2) 34 (9%) 295 (77%) 28·1 (5·2) 3 (1–5) 27·4 (26·5–28·4) 160·3 (157·3–163·5)
Controls 468 63·6 (5·2) 35 (7%) 361 (77%) 27·5 (5·4) ·· 26·8 (26·0–27·7) 160·6 (157·9–163·3)
PPHV, Netherlands11
Cases 77 54·5 (3·3) ·· 77 (100%) 26·4 (4·2) 5 (3–8) 23·9 (21·9–26·1) 135·1 (129·7–140·7)
Controls 167 54·4 (3·8) ·· 167 (100%) 26·4 (4·3) ·· 22·0 (20·8–23·3) 130·8 (127·6–134·0)
Prospect-EPIC, Netherlands11
Cases 15 54·3 (6·1) 1 (7%) 15 (100%) 25·4 (4·1) 2 (2–3) 18·5 (15·3–22·3) 109·0 (99·2–119·8)
Controls 35 54·4 (6·2) 4 (11%) 35 (100%) 26·4 (4·7) ·· 18·9 (16·7–21·5) 107·8 (102·7–113·3)
SOF, USA26
Cases 101 70·8 (4·7) 18 (18%) 87 (86%) 27·7 (5·3) 2 (1–4) 14·8 (14·0–15·7) 139·5 (133·6–145·6)
Controls 235 71·8 (4·9) 53 (23%) 203 (86%) 26·5 (4·3) ·· 14·6 (13·9–15·2) 136·1 (132·0–140·4)
WHI-OS, USA21
Cases 379 65·8 (7·2) 55 (15%) 268 (71%) 28·4 (6·3) 3 (2–4) 17·3 (16·7–17·9) 144·4 (141·5–147·4)
Controls 436 64·5 (7·4) 65 (15%) 282 (65%) 27·7 (6·6) ·· 17·1 (16·5–17·7) 145·0 (142·5–147·6)
Values are mean (SD) unless otherwise indicated, percentages exclude women with missing values. *Median (inter-quartile range) time between blood collection and diagnosis for cases. Numbers are for women 
with an IGF1 measurement. EPIC=European Prospective Investigation into Cancer and Nutrition. KKH=Danish Diet, Cancer, and Health study. KP-OFAS=Kaiser Permanente-Orentreich Foundation Study. 
MCCS=Melbourne Collaborative Cohort Study. NYU WHS=New York University Women’s Health Study. ORDET=Study of Hormones and Diet in the Etiology of Breast Tumours. PLCO=Prostate, Lung, Colorectal, 
and Ovarian Cancer Screening Trial. PPHV=Monitoring Project on Cardiovascular Disease Risk Factors; SOF=Study of Osteoporotic Fractures. WHI-OS=Women’s Health Initiative, Observational Study. 
Table 3: Participant characteristics by study and case-control status
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18·4–20·3) to 33·9 (32·9–34·9) nmol/L for premenopausal 
women, and from 14·6 (13·9–15·2) to 28·2 (24·9–31·8) 
nmol/L for postmenopausal women. Geometric mean 
concentrations of IGFBP3 ranged from 68·0 (95% CI 
65·7–70·4) to 179·4 (175·9–183·0) nmol/L for 
premenopausal women and from 69·7 (66·8–72·7) to 
160·6 (157·9–163·3) nmol/L for postmenopausal women. 
Data on IGF1 and IGFBP3 were available for 10 022 and 
9889 controls, respectively (these numbers are larger 
than those for the matched-set analyses because data for 
unmatched controls were included in the cross-sectional 
analyses). IGF1 and IGFBP3 were associated with each 
other, with correlations of 0·38 and 0·50 (data not shown) 
in premenopausal and postmenopausal women, 
respectively (both p<0·0001). The associations of IGF1 
with selected reproductive and other factors in control 
women are shown in ﬁ gure 1 (equivalent analyses for 
IGFBP3 are in the webappendix p 2). Geometric mean 
IGF1 was 26% lower for women aged 65 years and above 
than for women aged less than 45 years; the other results 
presented in ﬁ gure 1 are adjusted for age. IGF1 was 7% 
higher in women who were at least 170 cm tall than in 
women who were less than 155 cm tall, and was higher in 
women with a BMI of 25·0–27·4 kg/m² than in thinner 
or more overweight women. IGF1 was higher in women 
who drank up to 19 g/d of alcohol than in women who 
did not drink or who drank at least 20 g/d of alcohol, and 
was 4% lower for women who had undergone menarche 
at ages 14 years and over than for women who had 
undergone menarche before age 12 years. IGF1 varied 
according to parity, but not in a clear pattern, and was 
positively associated with age at ﬁ rst full-term pregnancy 
among parous women. For postmenopausal women, 
IGF1 was higher for those who had had their menopause 
most recently. IGF1 was higher for women who had 
previously used hormonal contraceptives than for those 
who had not. IGF1 was not signiﬁ cantly associated with 
smoking, family history of breast cancer, type of 
menopause, or previous use of hormonal therapy for 
menopause. The associations of IGF1 with other factors 
were similar in premenopausal and postmenopausal 
women (results not shown). Variation in IGFBP3 
concentrations by breast-cancer risk factors was less 
pronounced than that for IGF1 (webappendix p 2). 
IGF1 was weakly positively associated with breast-cancer 
risk for premenopausal women (test for trend, p=0·050) 
and strongly positively associated with breast-cancer risk 
for postmenopausal women (test for trend p=0·0002; 
ﬁ gure 2); the test for heterogeneity by menopausal status 
at blood collection was not statistically signiﬁ cant (test for 
heterogeneity p=0·894). In the individual studies, the ORs 
for the linear trend for premenopausal women ranged 
from 0·72 to 2·69, with an overall estimate of 1·18 (95% 
CI 1·00–1·40), and the median ratio of the IGF1 
concentration in the top versus the lowest ﬁ fth was 2·3 
(ﬁ gure 3A). The ORs for the linear trend for 
postmenopausal women ranged from 0·43 to 2·73, with 
an overall estimate of 1·30 (95% CI 1·13–1·49), and the 
median ratio of the IGF1 concentration in the top versus 
the lowest ﬁ fth was 2·4 (ﬁ gure 3B). In the combined 
analysis of premenopausal and postmenopausal women, 
those in the highest ﬁ fth of IGF1 had an OR of 1·28 
(95% CI 1·14–1·44) compared with women in the lowest 
ﬁ fth of IGF1 (test for trend, p<0·0001; ﬁ gure 2).
IGFBP3 was not associated with breast-cancer risk for 
premenopausal women (ﬁ gure 2), but was associated with 
risk for postmenopausal women (OR in the highest ﬁ fth 
compared with the lowest of 1·23 (95% CI 1·04–1·45, test 
for trend p=0·012; test for heterogeneity by menopausal 
status at blood collection p=0·511). In the combined 
analysis of premenopausal and postmenopausal women, 
See Online for webappendix
Figure 2: Odds ratios (OR) for breast cancer associated with IGF1 and IGFBP3 among premenopausal women 
(at blood collection), postmenopausal women (at blood collection), and all women
The black squares indicate the ORs and the horizontal lines show the 95% CIs. The area of each square is 
proportional to the amount of statistical information (inverse of the variance of the logarithm of the OR). 
Estimates are from conditional logistic regression on case-control sets matched within each study.
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those in the highest ﬁ fth of IGFBP3 had an OR of 1·13 
(95% CI 0·99–1·28) compared with women in the lowest 
ﬁ fth (test for trend p=0·062). 
Measurements of both IGF1 and IGFBP3 in complete 
matched sets were available for 4727 cases and 
9196 controls. Adjustment of the association between 
IGF1 and breast-cancer risk for IGFBP3 had no signiﬁ cant 
eﬀ ect on the OR; the OR for linear trend before adjustment 
was 1·24 (95% CI 1·11–1·38) and after adjustment was 
1·24 (1·10–1·41). By contrast, adjustment of the association 
between IGFBP3 and breast-cancer risk for IGF1 reduced 
the OR for linear trend from 1·12 (95% CI 1·00–1·26) to 
0·99 (0·87–1·14). Analyses of breast-cancer risk in relation 
to the molar ratio of IGF1 to IGFBP3 showed a signiﬁ cant 
positive association, but the magnitude was less than for 
the analyses of IGF1; ORs in increasing ﬁ fths of the ratio 
were 1·17 (95% CI 1·04–1·32), 1·12 (0·99–1·26), 
1·14 (1·01–1·29) and 1·23 (1·08–1·40) (test for trend 
p=0·009). Further stratiﬁ ed analyses showed that IGFBP3 
was not associated with breast-cancer risk within thirds of 
IGF1 (webappendix p 6). 
Figure 4 shows the associations with breast cancer of 
an 80 percentile diﬀ erence in IGF1 according to 
subgroups of various factors. The ORs varied according 
to oestrogen-receptor status; the OR for a linear trend in 
IGF1 was signiﬁ cant among oestrogen-receptor positive 
cases (OR 1·38, 95% CI 1·14–1·68), but not for oestrogen-
receptor negative tumours (OR 0·80, 0·57–1·13) and the 
test for heterogeneity was signiﬁ cant (p=0·007). For the 
other factors there was no signiﬁ cant heterogeneity in 
the association of IGF1 with breast-cancer risk. 
We examined the eﬀ ect on the association of IGF1 with 
breast-cancer risk of adjustment, one factor at a time, for 
height, age at menarche, number of full-term pregnancies, 
age at ﬁ rst full-term pregnancy, use of hormonal 
contraceptives, type of menopause (postmenopausal only), 
time since menopause (postmenopausal only), previous 
use of hormonal therapy for menopause (postmenopausal 
only), BMI (premenopausal and postmenopausal analysed 
separately), plasma oestradiol concentration (post-
menopausal only), plasma testosterone concentration 
(postmenopausal only), time of day of blood collection, and 
the phase of the menstrual cycle at blood collection 
(premenopausal only). None of these adjustments altered 
the OR for IGF1 and breast cancer by more than 2% (data 
not shown) with the exception of adjustment for 
testosterone in postmenopausal women, which reduced 
the OR for an 80 percentile diﬀ erence in IGF1 from 1·30 
(95% CI 1·08–1·55) to 1·24 (1·04–1·49). 
The relationship of IGF1 with breast-cancer risk for 
postmenopausal women was examined together with the 
associations with oestradiol and testosterone (table 4). In 
both these joint analyses, the OR increased fairly 
consistently across thirds of concentrations of both IGF1 
and the sex hormone, with no signiﬁ cant interaction. 
IGFBP3 was not signiﬁ cantly associated with breast-
cancer risk in any study of premenopausal women, and 
was signiﬁ cantly positively associated with risk in three 
out of 15 studies of postmenopausal women (webappendix 
pp 3,4). There was signiﬁ cant heterogeneity in the 
association of IGFBP3 with breast-cancer risk according 
to oestrogen receptor status; IGFBP3 was non-signiﬁ cantly 
positively associated with risk for oestrogen-receptor-
positive breast cancer and non-signiﬁ cantly inversely 
associated with risk for oestrogen-receptor-negative breast 
cancer (test for heterogeneity p=0·039; webappendix p 5).
Discussion
The results of this collaborative analysis show that plasma 
concentrations of IGF1 are positively associated with 
breast-cancer risk. The association is not substantially 
Figure 3: Odds ratios (OR) for breast cancer associated with IGF1 concentrations in women who were 
premenopausal at blood collection (A), and postmenopausal at blood collection (B) 
The OR is the estimate of the linear trend for IGF1 obtained by replacing the categorical variables representing the 
ﬁ fths of concentration in controls by a continuous variable scored as 0, 0·25, 0·5, 0·75, and 1. The black squares 
indicate the ORs and the horizontal lines show the 95% CIs. The area of each square is proportional to the amount 
of statistical information (inverse of the variance of the logarithm of the OR). The diamonds indicate the OR and 
95% CI for all studies combined. Estimates are from conditional logistic regression on case-control sets matched 
within each study. EPIC=European Prospective Investigation into Cancer and Nutrition. KKH=Danish Diet, Cancer, and 
Health study. KP-OFAS=Kaiser Permanente-Orentreich Foundation Study. MCCS=Melbourne Collaborative Cohort Study. 
NYU WHS=New York University Women’s Health Study. ORDET=Study of Hormones and Diet in the Etiology of Breast 
Tumours. PLCO=Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. PPHV=Monitoring Project on Cardiovascular 
Disease Risk Factors. SOF=Study of Osteoporotic Fractures. WHI-OS=Women’s Health Initiative, Observational Study.
Study OR (95% CI)Cases/
controls
Ratio of median
concentrations:
top–bottom ﬁfth
OR and 95% CI
CLUE I and CLUE II, USA17 87/87 2·6 1·41 (0·55–3·63)
EPIC, Europe16 409/793 2·2 1·13 (0·78–1·63)
Guernsey, UK13 69/200 2·0 1·24 (0·56–2·77)
Janus Biobank, Norway20 323/639 2·0 1·21 (0·81–1·80)
KP-OFAS, USA9 89/89 2·4 2·69 (0·93–7·78)
Malmo-Umea, Sweden8 141/256 2·6 1·15 (0·63–2·08)
MCCS, Australia19 160/594 2·3 0·72 (0·44–1·20)
Nurses’ Health Study, USA6,15 194/262 2·4 2·01 (1·06–3·81)
Nurses’ Health Study II, USA18 231/454 2·2 0·81 (0·49–1·33)
NYU WHS, USA7 172/483 2·3 1·34 (0·79–2·28)
ORDET, Italy10 62/239 2·6 2·64 (1·03–6·80)
All studies 1937/4096  1·18 (1·00–1·40)
CLUE I and CLUE II, USA17 73/73 2·6 2·20 (0·78–6·19)
EPIC, Europe16 677/1302 2·3 1·48 (1·11–1·97)
Guernsey, UK13 47/139 2·3 1·00 (0·38–2·60)
KKH, Denmark12 195/195 1·9 1·46 (0·80–2·66)
KP-OFAS, USA9 27/27 2·1 0·43 (0·10–1·86)
Malmo-Umea, Sweden8 222/401 3·2 1·12 (0·68–1·84)
MCCS, Australia19 257/993 2·6 1·64 (1·10–2·46)
Nurses’ Health Study, USA6,15 239/470 2·6 1·11 (0·70–1·76)
NYU WHS, USA7 98/171 2·4 1·32 (0·63–2·77)
ORDET, Italy10 60/220 2·9 0·75 (0·34–1·64)
PLCO, USA22 386/468 2·3 1·28 (0·87–1·88)
PPHV, Netherlands11 77/167 2·4 2·73 (1·24–5·99)
Prospect-EPIC, Netherlands11 15/35 2·7 1·13 (0·16–7·83)
SOF, USA26 101/235 2·3 1·11 (0·56–2·19)
WHI-OS, USA21 379/436 2·4 1·02 (0·68–1·52)
All studies 2853/5332  1·30 (1·13–1·49)
0·25 0·5 1 2 4
B
A
Articles
538 www.thelancet.com/oncology   Vol 11   June 2010
modiﬁ ed by menopausal status at blood collection or by 
IGFBP3 concentrations, but seems to be conﬁ ned to 
oestrogen-receptor-positive tumours.
The strengths of our study are that the data and plasma 
samples were all collected prospectively, that it includes 
almost all the available data from published studies 
worldwide, and that we were able to adjust for other 
potential risk factors, including endogenous sex 
hormones. A potential weakness is that the study designs 
and methods for measuring IGF1 and IGFBP3 and other 
risk factors were not standardised. IGF1 and IGFBP3 
concentrations varied substantially between studies, and 
this is likely to reﬂ ect diﬀ erences in assay methods. Our 
analysis allowed for this by deﬁ ning study-speciﬁ c 
quintiles of IGF1 and IGFBP3 concentrations. This 
method assumes the true concentrations across the 
quintiles are similar in all the studies, and if this 
assumption is not correct then the estimates of ORs 
might be biased.27 However, because heterogeneity 
between studies in risk estimates was not evident, this 
assumption does seem reasonable. There was some 
evidence of heterogeneity between studies in some of the 
cross-sectional analyses, suggesting that caution should 
be maintained in the interpretation of these analyses.
Previous studies have examined the associations of 
IGF1 with other factors. Relevant publications are cited 
below, but it should be noted that some of these are from 
the studies contributing to this collaborative analysis.
IGF1 was inversely associated with age, with no obvious 
additional decline in concentrations around age 50 years, 
suggesting that menopause itself does not have a marked 
eﬀ ect on IGF1. This is consistent with previous 
observations.5,28–32
IGF1 was 7% higher in the tallest women than in the 
shortest women. No signiﬁ cant association of IGF1 with 
height was noted in two previous analyses in adults,29,33 
but these results might be compatible with the small 
association noted in the current analysis. IGF1 was 
higher in women with a BMI of 25·0 to 27·4 kg/m² than 
in thinner or more overweight women, as described 
previously.34 Most circulating IGF1 is produced by the 
liver, and it is possible that a low BMI is associated with 
low IGF1 synthesis due to a relatively low supply of 
nutrients to the liver, whereas obesity is associated with 
low IGF1 synthesis in the liver due to compromised liver 
function.35
IGF1 was not associated with smoking, consistent with 
previous observations.29,30,36 In relation to alcohol, IGF1 
was higher for women who drank a small amount than 
for those who drank no alcohol or those who drank 20 g or 
more per day. Other observational studies had similar 
results.29,37–40 In randomised trials, 15 g/d of alcohol had no 
eﬀ ect on IGF1 in postmenopausal women, whereas 30 g/d 
caused a decrease in IGF1 by 9·5% for premenopausal 
women and by 4·9% for postmenopausal women.41,42 
IGF1 did not diﬀ er between women with or without a 
ﬁ rst-degree family history of breast cancer. The inverse 
Figure 4: Odds ratios (OR) for breast cancer associated with IGF1 concentration, according to menopausal 
status at blood collection and other factors
The OR is the estimate of the linear trend obtained by replacing the categorical variables representing the ﬁ fths of 
IGF1 concentration in controls by a continuous variable scored as 0, 0·25, 0·5, 0·75 and 1. Black squares indicate 
the OR and the horizontal lines show the 95% CIs. The area of each square is proportional to the amount of 
statistical information (inverse of the variance of the logarithm of the OR). The vertical dotted line indicates the OR 
for all studies. Tests for heterogeneity are for the diﬀ erence in the association of IGF1 with breast-cancer risk 
between subgroups. Estimates are from conditional logistic regression on case-control sets matched within each 
study. HRT=Hormone replacement therapy.
Factor and subset Cases/Controls OR (95% CI) OR and 95% CI
All studies
Menopausal status
Pre-menopausal
Postmenopausal
Age at diagnosis (years)
<50
≥50
Years from blood collection to diagnosis
<4 
≥4 
Stage of disease
In situ
Invasive
Oestrogen receptors
Positive
Negative
Body-mass index
<25 kg/m2
≥25 kg/m2
Smoking
Never or past smoker
Current smoker
Usual alcohol consumption
<10 g ethanol per day
≥10 g ethanol per day
Mother or sister with breast cancer
No
Yes
Age at menarche (years)
<14 
≥14 
Parity
Nulliparous
Parous
Age at ﬁrst birth (years)
<25 
≥25 
Type of menopause
Natural
Other
Use of oral contraceptives
Never user
Past user
HRT use among natural postmenopausal women
Never user
Past user
4790/9428
1937/4096
2853/5332
1071/2286
3719/7142
2627/5076
2163/4352
395/741
3628/7222
1414/2702
479/948
1918/4112
2411/4475
3547/7007
660/1224
2627/5422
 999/1815
1690/3363
389/496
2809/5411
1357/2934
640/1159
3490/6941
1532/2945
1755/2958
2260/4201
522/971
2042/4025
1618/3533
1460/2581
384/583
1·25 (1·13–1·39)
1·18 (1·00–1·40)
1·30 (1·13–1·49)
χ21 het=0·74; p=0·390
1·15 (0·92–1·44)
1·28 (1·14–1·45)
χ21 het=0·70; p=0·404
1·17 (1·01–1·35)
1·36 (1·16–1·59)
χ21 het=1·89; p=0·169
1·37 (0·94–1·98)
1·25 (1·11–1·42)
χ21 het=0·18; p=0·671
1·38 (1·14–1·68)
0·80 (0·57–1·13)
χ21 het=7·37; p=0·007
1·15 (0·98–1·36)
1·32 (1·13–1·53)
χ21 het=1·45; p=0·229
1·24 (1·10–1·40)
1·17 (0·89–1·53)
χ21 het=0·18; p=0·674
1·17 (1·02–1·35)
1·26 (1·00–1·59)
χ21 het=0·30; p=0·584
1·15 (0·96–1·37)
1·62 (1·09–2·39)
χ21 het=2·56; p=0·110
1·20 (1·05–1·38)
1·29 (1·06–1·56)
χ21 het=0·34; p=0·562
1·38 (1·03–1·83)
1·19 (1·05–1·35)
χ21 het=0·85; p=0·357
1·19 (0·99–1·43)
1·20 (1·00–1·43)
χ21 het=0·002; p=0·964
1·25 (1·07–1·45)
1·41 (1·03–1·92)
χ21 het=0·49; p=0·483
1·18 (1·01–1·39)
1·32 (1·10–1·57)
χ21 het=0·84; p=0·361
1·26 (1·04–1·53)
1·28 (0·88–1·86)
χ21 het=0·005; p=0·946
                                    
                                                            
0·25 0·5 1 2 4
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association we observed between IGF1 and age at menarche 
has been noted previously.43,44 We observed a non-linear 
association between IGF1 and parity, with the lowest 
concentrations for women who had four or more full-term 
pregnancies; previous studies have not reported any 
associations between IGF1 and parity.30,43–45 IGF1 was also 
positively associated with age at ﬁ rst full-term pregnancy. 
IGF1 was not associated with type of menopause, but in 
postmenopausal women was higher in those who had 
menopause most recently. IGF1 was marginally higher for 
women who had previously used hormonal contraceptives 
than for women who had not, but did not vary according to 
previous use of hormonal therapy for menopause. In 
future analyses we will examine the relationships of IGF1 
with endogenous sex hormones.
The associations of IGF1 with height, age at menarche, 
age at ﬁ rst full-term pregnancy, and time since 
menopause are compatible with the possibility that these 
factors aﬀ ect breast-cancer risk partly through their 
relationships with IGF1. 
IGF1 concentrations were positively associated with 
breast-cancer risk, with a highly signiﬁ cant trend and no 
evidence of heterogeneity between studies. Women in the 
highest ﬁ fth of IGF1 had a 28% higher risk of breast 
cancer than women in the lowest ﬁ fth. This association 
did not vary signiﬁ cantly according to menopausal status 
at blood collection or according to the risk factors for 
breast cancer examined, and was not attenuated by 
adjustment for other risk factors including IGFBP3, 
reproductive factors, and, for postmenopausal women, 
BMI, oestradiol, and testosterone. If the association was 
due to an eﬀ ect of preclinical tumours on IGF1 (reverse 
causality),46 then it would be expected to be weaker in those 
with a greater time interval between blood collection and 
diagnosis. This was not the case, and the association was 
highly signiﬁ cant in patients from whom blood had been 
collected at least 4 years before diagnosis. 
A previous meta-analysis based on studies published up 
to 2006 concluded that the association of IGF1 with breast-
cancer risk is limited to premenopausal women,47 but our 
analysis includes four large more recent studies with over 
1500 additional patients and shows a clear association of 
IGF1 with breast-cancer risk in postmenopausal women. 
Our analyses were all based on a single hormone 
measure for each woman. Measurements of hormone 
concentrations are subject to largely random error 
associated with assay variation and ﬂ uctuations in 
plasma concentrations within individual women. Five 
studies have reported the reproducibility of IGF1 over 
periods of between 1 and 15 years in samples of between 
13 and 138 women. The correlations (intra-class or 
Spearman) between baseline and repeat measures 
ranged from approximately 0·4 to 0·9 over 1 to 
15 years.10,17,19,48–50 It is therefore likely that the observed 
association between IGF1 concentrations and breast-
cancer risk is an underestimate of the true association, 
but more reproducibility data are required. 
The association of IGF1 with breast-cancer risk was 
conﬁ ned to oestrogen-receptor-positive tumours. Further 
work is needed to examine the potential biological basis 
for this observation. Laboratory studies have shown that 
oestrogen increases IGF receptor levels in breast-cancer 
cells,51 whereas in oestrogen-receptor-negative breast-
cancer cells the levels of IGF1 receptor are decreased, and 
IGF1 is non-mitogenic.52 
IGFBP3 was positively associated with breast-cancer 
risk, but this association was weak, and was eliminated 
by adjustment for IGF1, suggesting that the association 
of IGFBP3 with risk is due to its positive correlation 
with IGF1. It seems that, at least in the current dataset, 
the IGFBP3 measures do not add substantial 
information in assessing the relationship of IGF1 with 
breast-cancer risk. In addition to its role in transporting 
IGF1, laboratory studies have shown that IGFBP3 can 
have direct eﬀ ects on cell behaviour which can promote 
apoptosis, but under other circumstances can act 
against apoptosis.53 Data on IGFBP-1 and IGFBP-2 have 
also been contributed for our collaborative analyses, but 
currently there are too few data to provide robust 
analyses. Better understanding of the roles of IGF-
binding proteins as potential modulators of the 
association between IGF1 and breast-cancer risk might 
come from further data on IGFBP1 and IGFBP2, from 
measures of intact IGFBP3,54 or from measures of 
bioavailable IGF1.55 
The OR for IGF1 is smaller than the ORs for both 
oestrogens and androgens and breast-cancer risk in 
postmenopausal women, which have been shown in data 
mostly from the same epidemiological studies; high 
concentrations of oestradiol and testosterone are 
associated with around a doubling in breast-cancer 
risk.25,56–58 In our analyses, adjustment for oestradiol and 
testosterone had little eﬀ ect on the association of IGF1 
with breast-cancer risk for postmenopausal women, and 
there was no evidence of an interaction between IGF1 
and oestradiol or testosterone in relation to breast-cancer 
risk. Nevertheless, a better understanding of the joint 
eﬀ ects of hormones on breast-cancer risk is needed.59
Low Medium High
Cases/
controls
OR (95% CI) Cases/
controls
OR (95% CI) Cases/
controls
OR (95% CI)
Thirds of oestradiol (test of interaction: χ24=2·31, p=0·679)
Low 176/474 1·00 (ref) 205/471 1·20 (0·94–1·53) 194/475 1·21 (0·94–1·55)
Medium 160/396 1·25 (0·96–1·63) 225/415 1·61 (1·26–2·06) 196/424 1·38 (1·07–1·77)
High 212/405 1·70 (1·32–2·19) 240/404 1·89 (1·47–2·43) 267/403 2·08 (1·62–2·67)
Thirds of testosterone (test of interaction: χ24=3·79, p=0·436)
Low 125/438 1·00 (ref) 156/424 1·27 (0·96–1·66) 157/378 1·47 (1·11–1·95)
Medium 152/404 1·35 (1·03–1·79) 181/389 1·65 (1·25–2·17) 181/392 1·62 (1·23–2·13)
High 175/345 1·88 (1·41–2·49) 214/385 2·01 (1·54–2·64) 227/426 1·91 (1·47–2·49)
Table 4: Relationships of IGF1 with breast-cancer risk among postmenopausal women, according to 
plasma concentrations of oestradiol and testosterone
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The association of IGF1 with breast-cancer risk was not 
altered by adjusting for age at menarche, parity, age at ﬁ rst 
full-term pregnancy, use of exogenous hormones, and 
BMI, suggesting that the relationship of IGF1 with breast-
cancer risk is not confounded by these other risk factors. 
This collaborative analysis has conﬁ rmed a positive 
association between IGF1 and breast cancer risk. It is 
not known whether this association is causal, but there 
are plausible biological mechanisms that could explain 
such an eﬀ ect.1,2 The magnitude of the observed 
association is modest, but the true association could be 
substantially larger because of measurement error, and 
further work is needed to reliably quantify the 
relationship. If the association is causal then it might 
have important implications for prevention. Plasma 
concentrations of IGF1 are inﬂ uenced by nutritional 
factors such as energy and protein intake,60 and the 
possibility of lowering breast-cancer risk by reducing 
IGF1 should be explored.
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